Literature DB >> 9297069

[Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide].

I Caesar1, V Gross, M Roth, T Andus, W Hohenberger, J Schölmerich.   

Abstract

BACKGROUND: Glucocorticoids are an effective treatment of ulcerative colitis. The occurrence of steroid side effects depends on dosage and duration of steroid treatment. It may be a high as 80%. A rare side effect of glucocorticoid therapy is steroid induced myopathia. There exists an acute and a chronic form of steroid induced myopathia. Chronic steroid myopathia affects mainly the proximal musculature of the lower and upper extremities and leads to proximal muscle weakness. Histologically, an atrophy of type IIb-muscle fibers can be found. Chronic steroid myopathia occurs after prolonged treatment with higher doses of glucocorticoids. CASE REPORT: The case report describes a 25 year old male patient with left-sided ulcerative colitis who developed chronic steroid myopathia after several months of glucocorticoid treatment. After switching from systemic steroids to budesonide the symptoms of myopathia disappeared. Left-sided ulcerative colitis remained in remission.
CONCLUSION: The case documents the disappearance of a severe steroid side effect after switching from a systemic steroid to budesonide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9297069     DOI: 10.1007/BF03044778

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  22 in total

1.  An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

Authors:  J E LENNARD-JONES; A J LONGMORE; A C NEWELL; C W WILSON; F A JONES
Journal:  Gut       Date:  1960-09       Impact factor: 23.059

2.  The muscle spindle in cortisone-induced muscular atrophy.

Authors:  L Z Stern; L K Hannapel
Journal:  Exp Neurol       Date:  1973-08       Impact factor: 5.330

3.  Muscle glycogen metabolism in steroid-induced myopathy of rabbits.

Authors:  S Shoji; A Takagi; H Sugita; Y Toyokura
Journal:  Exp Neurol       Date:  1974-10       Impact factor: 5.330

4.  Some observations on the hazards of corticosteroid therapy in patients with inflammatory bowel disease.

Authors:  M J Goldstein; E A Gelzayd; J B Kirsner
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1967 Mar-Apr

5.  Steroid myopathy. Clinical, histologic and cytologic observations.

Authors:  A K Afifi; R A Bergman; J C Harvey
Journal:  Johns Hopkins Med J       Date:  1968-10

6.  Treatment of active Crohn's disease with an oral slow-release budesonide formulation.

Authors:  M Roth; V Gross; J Schölmerich; B Ueberschaer; K Ewe
Journal:  Am J Gastroenterol       Date:  1993-06       Impact factor: 10.864

7.  Acute hydrocortisone myopathy.

Authors:  W Van Marle; K L Woods
Journal:  Br Med J       Date:  1980-07-26

8.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

9.  Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors.

Authors:  D C DuBois; R R Almon
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

10.  The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis.

Authors:  D J Adler; B I Korelitz
Journal:  Am J Gastroenterol       Date:  1990-06       Impact factor: 10.864

View more
  1 in total

1.  Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.

Authors:  T Andus; V Gross; I Caesar; H J Schulz; H Lochs; W D Strohm; M Gierend; A Weber; K Ewe; J Schölmerich
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.